The effect of laser therapy on the orofacial pain

The clinical trial to compare the effect of laser therapy associated with drug therapy on relieving the most common orofacial pains in patients who have trigeminel neuralgia, atypical facial pain and myofacial pain dysfunction syndrome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201201018585N1

Enrollment

Registered

2012-02-01

Start date

2010-01-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Trigeminal Neuralgia. Condition 2: Myofacial Pain Dysfunction Syndroms. Condition 3: Atypical Facial Pain. Diseases of the nervous system,disorders of 5th cranial nerve Diseases of the musculoskeletal system and connective tissue, Other disorders of muscle Nerve, nerve root and plexus disorders, disorders of 5th cranial nerve

Interventions

Intervention 1: Intervention group: 10 section of Low level laser therapy (LLLT) + standard drug therapy of their pain The type of laser is Ga-AS (Device model: DLT 101) with pulse mode-mod II of ex

Treatment - Other

Treatment - Drugs

Intervention group: 10 section of Low level laser therapy (LLLT) + standard drug therapy of their pain The type of laser is Ga-AS (Device model: DLT 101) with pulse mode-mod II of exposure. Th

Control group: Sham laser + Standard drug therapy of their pain Diagnosis of orofacial pain: Trigeminal neuralgia (TN) is the most common of the cranial neuralgias and chiefly affects individuals

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Having the criteria of each of the pains including Trigeminel Neuralgia, Atypical Facial Pain and Myofacial Pain Dysfunction Syndrome? The patients who have not a good response to routine drug therapy? Exclusion criteria: the patients who have a good response to previous drug therapy? The pregnant women

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The amount of pain. Timepoint: Before and after intervention and 2-4 months after intervention. Method of measurement: Visual Analogue Scale.	—

Secondary

Measure	Time frame
The metabolit of serotoninlike 5-hydroxy indole acetic acid (5-HIAA). Timepoint: Before ,after,2-4 month after intervention. Method of measurement: 24-hour urine.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Fatemeh Lavaee

Shiraz Dental School

lavaeef@sums.ac.ir; fatemeh.lavaee@yahoo.com+98 71 1631 9309

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026